Nanobiotix Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Nanobiotix wird ein Gewinn- und Umsatzwachstum von 13.7% bzw. 8.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 15.7% pro Jahr wachsen soll.

Wichtige Informationen

23.5%

Wachstumsrate der Gewinne

25.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	14.4%
Wachstumsrate der Einnahmen	8.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

May 14

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:NANO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	57	-8	51	-5	3
12/31/2025	51	-31	-41	-44	5
12/31/2024	30	-42	-48	-40	5
12/31/2023	36	-40	-13	-12	N/A
9/30/2023	21	-49	-25	-25	N/A
6/30/2023	7	-59	-37	-37	N/A
3/31/2023	6	-58	-37	-37	N/A
12/31/2022	5	-57	-37	-37	N/A
9/30/2022	4	-50	-35	-35	N/A
6/30/2022	3	-43	-33	-32	N/A
3/31/2022	3	-45	-31	-31	N/A
12/31/2021	3	-47	-30	-30	N/A
9/30/2021	2	-45	-30	-30	N/A
6/30/2021	2	-43	-30	-30	N/A
3/31/2021	2	-39	-29	-29	N/A
12/31/2020	2	-34	-28	-28	N/A
9/30/2020	2	-41	-31	-30	N/A
6/30/2020	2	-48	-33	-33	N/A
3/31/2020	2	-49	-38	-37	N/A
12/31/2019	3	-51	-43	-41	N/A
9/30/2019	3	-46	-38	-37	N/A
6/30/2019	3	-42	-34	-33	N/A
3/31/2019	3	-36	-30	-30	N/A
12/31/2018	3	-30	-26	-26	N/A
9/30/2018	4	-28	-25	-24	N/A
6/30/2018	4	-27	-24	-22	N/A
3/31/2018	4	-26	-23	-22	N/A
12/31/2017	4	-26	-22	-21	N/A
9/30/2017	4	-25	N/A	-20	N/A
6/30/2017	4	-24	N/A	-19	N/A
3/31/2017	5	-23	N/A	-19	N/A
12/31/2016	5	-22	N/A	-18	N/A
9/30/2016	5	-21	N/A	-19	N/A
6/30/2016	5	-19	N/A	-20	N/A
3/31/2016	5	-18	N/A	-19	N/A
12/31/2015	4	-17	N/A	-17	N/A
9/30/2015	4	-15	N/A	-15	N/A
6/30/2015	3	-13	N/A	-12	N/A
3/31/2015	3	-11	N/A	-11	N/A
12/31/2014	3	-10	N/A	-9	N/A
9/30/2014	2	-9	N/A	-8	N/A
6/30/2014	2	-8	N/A	-8	N/A
3/31/2014	2	-8	N/A	-7	N/A
12/31/2013	2	-8	N/A	-7	N/A
9/30/2013	1	-8	N/A	-6	N/A
6/30/2013	1	-7	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NANO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: NANO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: NANO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: NANODie Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.8% pro Jahr).

Hohe Wachstumseinnahmen: NANODie Einnahmen des Unternehmens (8.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NANO in 3 Jahren voraussichtlich hoch sein wird

Nanobiotix Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 16%, EPS downgraded

Forecast to breakeven in 2026

Consensus revenue estimates fall by 24%

Consensus revenue estimates increase by 26%

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Recent updates

Consensus revenue estimates increase by 16%, EPS downgraded

New minor risk - Share price stability

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

Price target increased by 15% to €25.17

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Price target decreased to €21.90

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Price target decreased to €22.90

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Price target decreased to €23.18

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Price target increased to €29.67

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Consensus EPS estimates fall to -€1.29

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.20

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Price target raised to €25.18

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

New 90-day high: €14.00